Oncologie

, Volume 14, Issue 1, pp 2–4

Mécanismes de résistances aux inhibiteurs de RAF : revue de la littérature

  • B. Rousseau pour l’Aerio
Revue de Presse / Press Review

Mechanisms of resistance to RAF inhibitors: literature review

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Aplin AE, Kaplan FM, Shao Y (2011) Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 131(9): 1817–1820PubMedCrossRefGoogle Scholar
  2. 2.
    Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507–2516PubMedCrossRefGoogle Scholar
  3. 3.
    Gopal YNV, Deng W, Woodman SE, et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in BRAF-mutant human cutaneous melanoma cells. Cancer Res 70(21): 8736–8747PubMedCrossRefGoogle Scholar
  4. 4.
    Jiang CC, Lai F, Thorne RF, et al. (2011) MEK-independent survival of BRAF V600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17(4): 721–730PubMedCrossRefGoogle Scholar
  5. 5.
    Johannessen CM, Boehm JS, Kim SY, et al. (2010) COT drives resistance to RAF inhibition through MAP-kinase pathway reactivation. Nature 468(7326): 968–972PubMedCrossRefGoogle Scholar
  6. 6.
    Nazarian R, Shi H, Wang Q, et al. (2010) Melanomas acquire resistance to BRAF V600E inhibition by RTK or NRAS upregulation. Nature 468(7326): 973–977PubMedCrossRefGoogle Scholar
  7. 7.
    Oikonomou E, Koc M, Sourkova V, et al. (2011) Selective BRAF V600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS ONE 6(6): e21632PubMedCrossRefGoogle Scholar
  8. 8.
    Poulikakos PI, Zhang C, Bollag G, et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287): 427–430PubMedCrossRefGoogle Scholar
  9. 9.
    Villanueva J, Vultur A, Lee JT, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF-kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6): 683–695PubMedCrossRefGoogle Scholar
  10. 10.
    Wagle N, Emery C, Berger MF, et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22): 3085–3096PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2012

Authors and Affiliations

  • B. Rousseau pour l’Aerio

There are no affiliations available

Personalised recommendations